Dendrite Awarded International Software License and Service Business by Leading Pharmaceutical Company.

Business Editors/Health/Medical Writers/High-Tech Writers

MORRISTOWN, N.J.--(BUSINESS WIRE)--Feb. 19, 2004

-

Initial 1,500 User Licenses to be Purchased for Deployment in

Mexico, Japan, and South Korea

Dendrite International, Inc. (NASDAQ: DRTE) announced that it has signed global software license and service agreements with one of the world's leading pharmaceutical companies. Dendrite's fourth quarter earnings call on January 29 included a discussion of this agreement.

Dendrite will serve as a key software and service provider to the company in markets outside the United States. The company, which has an international sales force totaling approximately 9,000, will purchase a minimum of 1,500 user licenses of Dendrite's leading sales force solutions-- including WebForce(TM), WebForce Express(TM), j-forceNET(TM), VisiForce(TM) and ForceAnalyzer(TM) sales effectiveness solutions--for deployment in Mexico, South Korea, and Japan. Licenses in Japan will be sold through Dendrite's Japanese distributor, as announced on October 30, 2003. The agreements also encompass a broad range of locally delivered support services, including implementation, training, ongoing facilities management, and production services.

"Pharmaceutical companies are increasingly making strategic vendor selections on a global basis in order to achieve operational and financial efficiencies," said John Bailye, Dendrite Chairman and CEO. "Dendrite has uniquely positioned itself to capitalize on this trend by providing clients with specialized software and service offerings, along with local expertise, in all major markets around the world. This new arrangement recognizes our ability to partner with customers on a global basis to meet their diverse international requirements."

Added Jean-Paul Modde, Dendrite Group President, International, "Over the past several years, this customer has been particularly impressed with our market knowledge and experience working with them in Latin America and parts of Europe, where we were already supporting over 1,400 users. Their confidence in our capabilities has prompted this new global relationship. We look forward to working with them on a worldwide basis, and believe this arrangement serves as an excellent model for engaging with other customers on a broader scale."

Global Solutions for Global Companies

Providing products and services to more than 100,000 pharmaceutical sales representatives and managers worldwide, Dendrite serves more than 150 companies, including all of the top 20 pharmaceutical companies, in more than 50 countries. Solutions covered under these new international agreements include:

-- WebForce: a comprehensive product suite that helps

pharmaceutical companies manage all aspects of sales force

activities by providing representatives and managers with a

single, centralized location from which to manage customer

relationships, access product information, evaluate

competitors, record and catalogue client and prospect data,

and access customer information

-- WebForce Express: featuring the robust functionality of

WebForce and requiring minimal configuration and customization

for rapid implementation

-- j-forceNET: a web-based sales force solution designed

specifically for the Asian market that enables pharmaceutical

companies to view sales data, enter call information, update

client profiles, access corporate resources, and effectively

communicate with the home office

-- VisiForce: a complete sales effectiveness system designed for

pharmaceutical companies in emerging markets

-- ForceAnalyzer: a flexible, easy-to-use data visualization and

analysis solution for management to monitor and analyze

promotional activities

Dendrite's offices in Mexico City; Osaka and Tokyo, Japan; and Seoul, South Korea will provide support services during the deployment of these initial licenses.

About Dendrite

Dendrite develops and delivers solutions that increase the productivity of sales, marketing, and clinical processes for pharmaceutical and other life science clients. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document contains forward-looking statements that are based on Dendrite International, Inc.'s current expectations, estimates and projections. The statements may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on major customers; changes in demand for our products and services attributable to the extended weakness experienced in the economy; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions, including the success of the June 2003 acquisition of Synavant and the risks associated with the integration of acquisitions; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; hostilities in the Middle East and Asia and resulting impact on our business and business and needs of our customers; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.